These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 10760109

  • 1. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients.
    Suliman ME, Qureshi AR, Bárány P, Stenvinkel P, Filho JC, Anderstam B, Heimbürger O, Lindholm B, Bergström J.
    Kidney Int; 2000 Apr; 57(4):1727-35. PubMed ID: 10760109
    [Abstract] [Full Text] [Related]

  • 2. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy.
    Suliman ME, Stenvinkel P, Heimbürger O, Bàràny P, Lindholm B, Bergström J.
    Am J Kidney Dis; 2002 Sep; 40(3):480-8. PubMed ID: 12200798
    [Abstract] [Full Text] [Related]

  • 3. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus.
    Suliman ME, Stenvinkel P, Bárány P, Heimbürger O, Anderstam B, Lindholm B.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S89-95. PubMed ID: 12612961
    [Abstract] [Full Text] [Related]

  • 4. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease.
    Suliman ME, Lindholm B, Bárány P, Bergström J.
    Clin Chem Lab Med; 2001 Aug; 39(8):734-8. PubMed ID: 11592443
    [Abstract] [Full Text] [Related]

  • 5. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.
    Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergström J.
    Kidney Int; 1998 Mar; 53(3):773-82. PubMed ID: 9507226
    [Abstract] [Full Text] [Related]

  • 6. Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy.
    Suliman ME, Stenvinkel P, Qureshi AR, Bárány P, Heimburger O, Anderstam B, Alvestrand A, Lindholm B.
    Am J Kidney Dis; 2004 Sep; 44(3):455-65. PubMed ID: 15332218
    [Abstract] [Full Text] [Related]

  • 7. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients.
    Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, Bergström J.
    J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S28-36. PubMed ID: 11792759
    [Abstract] [Full Text] [Related]

  • 8. Low total plasma homocysteine level in relation to malnutrition, inflammation, and outcome in hemodialysis patients.
    Akgul A, Bilgic A, Sezer S, Arat Z, Ozdemir FN, Haberal M.
    J Ren Nutr; 2008 Jul; 18(4):338-46. PubMed ID: 18558298
    [Abstract] [Full Text] [Related]

  • 9. Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease.
    Suliman ME, Bárány P, Divino Filho JC, Qureshi AR, Stenvinkel P, Heimbürger O, Anderstam B, Lindholm B, Bergström J.
    Nephrol Dial Transplant; 2002 Jun; 17(6):1050-6. PubMed ID: 12032196
    [Abstract] [Full Text] [Related]

  • 10. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients.
    Fellah H, Feki M, Hsairi M, Sanhaji H, Kaabachi N, Ben Abdallah T, Massy ZA, Ben Maiz H, Lacour B, Mebazaa A.
    Clin Chem Lab Med; 2003 May; 41(5):675-80. PubMed ID: 12812266
    [Abstract] [Full Text] [Related]

  • 11. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.
    Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP.
    Kidney Int; 2001 Sep; 60(3):1106-13. PubMed ID: 11532106
    [Abstract] [Full Text] [Related]

  • 12. [Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients].
    Armada E, Pérez Melón C, Otero A, Gayoso P, Rodríguez M, Esteban Morcillo J.
    Nefrologia; 2001 Sep; 21(2):167-73. PubMed ID: 11464650
    [Abstract] [Full Text] [Related]

  • 13. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri-Imad F, Bommareddy G, Chassaing C, Wainer I, Loya A, Cary D, Barker LF, Assefi A, Greenspan R, Mahoney D, Wilcox CS.
    J Nephrol; 2003 Sep; 16(4):522-34. PubMed ID: 14696754
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
    Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B.
    Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
    [Abstract] [Full Text] [Related]

  • 18. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus.
    Wollesen F, Brattström L, Refsum H, Ueland PM, Berglund L, Berne C.
    Kidney Int; 1999 Mar; 55(3):1028-35. PubMed ID: 10027940
    [Abstract] [Full Text] [Related]

  • 19. Parenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease.
    Kaplan LN, Mamer OA, Hoffer LJ.
    Clin Invest Med; 2001 Feb; 24(1):5-11. PubMed ID: 11266032
    [Abstract] [Full Text] [Related]

  • 20. Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins.
    Tremblay R, Bonnardeaux A, Geadah D, Busque L, Lebrun M, Ouimet D, Leblanc M.
    Kidney Int; 2000 Aug; 58(2):851-8. PubMed ID: 10916110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.